TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03567941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet orally administered under fasting
Study: NCT03567941
Drug: Hydrocodon bitartrate-acetaminophen arm 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet orally administered under fasted conditions
Study: NCT03567941
Drug: Hydrocodon bitartrate-acetaminophen arm 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet orally administered under fed conditions
Study: NCT03567941
Drug: Reference
Normalized name: Loreal Preference Dark Auburn 4R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet orally administered under fasted conditions
Study: NCT00520091
Drug: CPT- 11
Approvals — FDA: no, EMA: no, PMDA: no
Description: 65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
Study: NCT00520091
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin
Study: NCT01149369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
Study: NCT01424397
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo intranasal
Study: NCT01601990
Drug: Placebo group(once daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.
Study: NCT01601990
Drug: LC15-0444 50mg qd
Approvals — FDA: no, EMA: no, PMDA: no
Description: eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks
Study: NCT00472043
Drug: PDT with Metvix 160 mg/g cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00472043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01529827
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04453345
Drug: thalidomide + prednisone + methotrexate
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: thalidomide 50-100mg daily at bedtime + prednisone 0.5mg/kg qod to 1mg/kg qd + methotrexate 10mg/m2 per week. 4 months one cycle, up to 3 cycles. After get partial remission, thalidomide maintenance will continue up to 2 years.
Study: NCT01935167
Drug: DW1029M 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DW1029M 150mg 2 tablets b.i.d
Study: NCT01935167
Drug: DW1029M 1200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DW1029M 300mg 2 tablets b.i.d
Study: NCT01624974
Drug: MK-1029
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1029 150 mg tablets taken QD
Study: NCT01624974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (matching the MK-1029 150 mg tablets) QD
Study: NCT02875366
Drug: LUM/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02875366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02463331
Drug: azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azathioprine 1-2mg/Kg/day until the end of the study
Study: NCT02545049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to be taken orally, once daily.
Study: NCT03550378
Drug: MEDI0382
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.
Study: NCT03550378
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SC placebo matched to MEDI0382 once daily for 32 days.
Study: NCT00343265
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT04203511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of placebo administered intravenously on Day 1 of each 28-day cycle for up to 12 cycles.
Study: NCT03917303
Drug: standard step-up care
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional step-up care starting with corticosteroids
Study: NCT00790426
Drug: TKI258
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00056095
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03780049
Drug: H101
Normalized name: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive H101 0.5ml dissolved in 10ml normal saline in each session of HAIC
Study: NCT03780049
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive normal saline 10ml in each session of HAIC
Study: NCT01140841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 2 tablets three times per day to be taken according to the same schedule as the active study drug.
Study: NCT02147678
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During anesthesia maintenance, all patients will be given remifentanil at the speed of 0.2\~0.4 μg/kg/min.
Study: NCT02147678
Drug: Anesthesia induction
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: For all patients, the induction protocol is midazolam 0.1 mg/kg, sufentanil 0.3 μg/kg, cisatracurium 0.15 mg/kg.
Study: NCT04247386
Drug: PEG-Mizone
Approvals — FDA: no, EMA: no, PMDA: no
Description: The evening before the colonoscopy:60gPEG-4000 was mixed with 0.6LMizone and 0.4L water.~On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 1.2LMizone and 0.8L water.
Study: NCT04247386
Drug: PEG-ELS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The evening before the colonoscopy:60gPEG-4000 was mixed with 1L water. On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 2L water.
Study: NCT01650558
Drug: Standard of Care prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily trimethoprim sulfamethoxazole
Study: NCT00420212
Drug: BG00012
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00420212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04142762
Drug: ABI-H2158
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-H2158 tablets
Study: NCT02730481
Drug: Oraxol
Normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
Study: NCT04142762
Drug: Ethinyl Estradiol / Levonorgestrel
Normalized name: ethinyl estradiol / levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinyl Estradiol / Levonorgestrel tablets
Study: NCT04142762
Drug: Placebo matching oral contraceptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching Ethinyl Estradiol / Levonorgestrel tablets
Study: NCT00526292
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day -6 cyclophosphamide 60mg/kg infused over 1 hour (dose adjusted for body weight) for 2 days
Study: NCT00946842
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
Study: NCT00946842
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
Study: NCT02462889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection
Study: NCT02483611
Drug: Isotonic Solution
Normalized name: Isotonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00976261
Drug: GSK1614235
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose lowering in Type 2 Diabetes Mellitus
Study: NCT03817931
Drug: Anticholinergic
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet taken once daily.
Study: NCT03817931
Drug: Beta-3 Agonists, Adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet taken once daily.
Study: NCT04169698
Drug: Alendronate 70Mg Tab
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonates
Study: NCT03418155
Drug: Treatment of TongBi placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TongBi placebo:0.31g,3times a day, oral, for 4 weeks.
Study: NCT04077021
Drug: CCW702
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational immunotherapy for prostate cancer
Study: NCT00151567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo of tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
Study: NCT01710904
Drug: Targinact® (oxycodone/naloxone)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01528618
Drug: 5-Fluorouracil and cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The FP regimen consists of 5-Fluorouracil 1,000 mg/m2/day which was administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1( 80 mg/m2 i.v. infusion for 4 h)
Study: NCT02130635
Drug: GSK2269557 500 MCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
Study: NCT02130635
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose administered using a matching dry powder inhaler device
Study: NCT02826746
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: the same bolus and infusion volumes of normal saline
Study: NCT02654782
Drug: 5% Human Albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid given for hemodynamic resuscitation based off of individual patient needs.
Study: NCT03085394
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intravenous administration of 10 ml saline
Study: NCT03206684
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight \<45kg were given 3mg once per chemotherapy cycle.
Study: NCT03074331
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg FDC tablet(s) administered orally once daily
Study: NCT00468052
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 microgram/kilogram as a bolus
Study: NCT00077493
Drug: BL22 immunotoxin
Normalized name: hepatitis B immunoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.
Study: NCT00296868
Drug: ascorbic acid (vitamin C) versus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00656994
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon placebo-matching tablets, orally, once nightly for up to 6 months
Study: NCT03189589
Drug: GSK2269557 500 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 500 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
Study: NCT01132391
Drug: Rectogesic® (glyceryl trinitrate 0.4% ointment)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg of ointment(1,5 mg of glyceryl trinitrate ) / 12h DURING 6 MONTHS
Study: NCT03189589
Drug: GSK2269557 750 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 750 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
Study: NCT03918967
Drug: CT-G11
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet of CT-G11 Experimental Drug
Study: NCT03918967
Drug: CT-G11 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet of Placebo
Study: NCT03918967
Drug: CT-G20 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet of Placebo
Study: NCT04138394
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive intravenous vitamin C (50 mg/kg every 6 hours for 96 hours).
Study: NCT04138394
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.
Study: NCT02204982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo (25 mg BID) administered orally in 28-day continuous treatment cycles.
Study: NCT02740231
Drug: JTA-004 intra-articular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will undergo a single injection of JTA-004 into the knee joint
Study: NCT01546753
Drug: Walnut Protein Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded study product dosing begins with a 1-day oral desensitization protocol to walnut for subjects in the active arm. Starting at 0.1 mg protein and increasing to a maximum of 6 mg or until allergic symptoms develop. Subjects continue daily dosing of blinded OIT (walnut) with build-up every 2 weeks to a maximum daily dose of 1500mg at week 34, followed by 4 weeks of daily maintenance dosing. OFC to walnut and second tree nut occurs at week 38 then treatment is unblinded and open-label maintenance dosing occurs.
Study: NCT02313220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and Subcutaneous use.
Study: NCT02513355
Drug: Changchun marina
Normalized name: Zostera marina whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg/m2,d1 and d8,q21d×4
Study: NCT01546753
Drug: Oat Powder (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded study product dosing begins with a one-day oral desensitization protocol with placebo (oat) powder. Subjects in the placebo group will undergo the same protocol as those in the active group with placebo OIT dosing. Unblinding to treatment assignment will occur after the 38 week oral food challenge. Placebo subjects will cross-over to active, open-label treatment with walnut powder after the 38 week oral food challenge. beginning with initial escalation day, through build-up and maintenance dosing per the same protocol sequence as noted for active, walnut powder. Subjects will complete an oral food challenge to walnut and the second tree nut at week 38 then will continue on long-term, open-label maintenance dosing until the end of study using same protocol design.
Study: NCT01546753
Drug: Open-label Walnut Protein Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label treatment phase begins after the 38 week oral food challenge with unblinding of treatment assignment. For those on active treatment, daily maintenance dosing occurs for up to a total of 298 weeks. For those on placebo treatment, cross-over to active, open-label treatment occurs using the same active treatment protocol. Placebo-crossover subjects will complete an oral food challenge to walnut and the second tree nut at week 38 of active therapy then continue on long-term, open-label maintenance dosing until the end of study using same protocol design. All subjects may reach a qualifying IgE to walnut/second tree nut early and will undergo an OFCs on and 4 weeks off OIT. All subjects will have OFCs on and 4 weeks off OIT at week 142 and at week 298, unless both walnut/second tree nut OFCs are passed at previous OFC prompting addition of these foods into the diet.
Study: NCT02607735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily with food
Study: NCT01590446
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection, Part 1 single dose and Part 2 multiple dose
Study: NCT01416818
Drug: Xiaoyao Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: herb extracts,were received two times a day for 12 weeks without dose changing.
Study: NCT01416818
Drug: Bupleurum+Ginkgo
Approvals — FDA: no, EMA: no, PMDA: no
Description: herb extracts, were received two times a day for 12 weeks without dose changing.
Study: NCT01416818
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo looked like herb extracts and were also received two times a day for 12 weeks without dose changing.
Study: NCT01646255
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal Patch~Size:~20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches
Study: NCT01376908
Drug: Kuvan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuvan® (sapropterin dihydrochloride) tablets will be administered orally at the dose of 10 mg/kg/day and will be escalated to 20 mg/kg/day if after 4 weeks a subject's Phe tolerance is not increased by at least 20% versus baseline.
Study: NCT00004172
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00093015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume and dose frequency changes resembling dosing in the active treatment group
Study: NCT00742391
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: two day treatment
Study: NCT01744340
Drug: Head and neck
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter~Dose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle
Study: NCT01744340
Drug: Colon- Closed as of May 2014
Normalized name: Bos Taurus Colon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle
Study: NCT02178592
Drug: DTG 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG is available as 50 mg film-coated tablet. DTG may be administered with or without food
Study: NCT02178592
Drug: EFV 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFV is supplied as film-coated capsule-shaped oral tablet containing 600 mg of EFV and must be administered without food
Study: NCT01346982
Drug: Silimarine
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir 600/100 mg + silimarine (150 mg every 8 hours)
Study: NCT03830086
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures together with Bupivacaine; and for general anesthesia for gynecological laparoscopic procedures, together with following drugs: Midazolam, Propofol, Rocuronium, Sevoflurane
Study: NCT03215017
Drug: Medication
Normalized name: Acne Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication to help control of the bowel movement (One or a combination of Loperamide, Sorbitol, Sterculia gum)
Study: NCT00392054
Drug: Conventional Antiarrhythmic Drug Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Arrhythmic Drugs per ACC/AHA 2006 Guidelines for the Management of Patients with AF
Study: NCT01302236
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/day for all as initial dose, 100mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
Study: NCT03315676
Drug: Oral Esomeprazol
Approvals — FDA: no, EMA: no, PMDA: no
Description: To examine the efficacy of oral Esomeprazol in patients with NSAIDs-induced Erosions and/or Ulcers
Study: NCT02569645
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg rosuvastatin orally once per day with or without food, swallowed whole (not chewed, crushed or divided) starting 2 weeks prior to the initiation of radiation therapy and stopped at 4 weeks after the completion of radiation. Total duration of Rosuvastatin is 11 weeks if 25 fractions of radiotherapy are given, or 12 weeks if 30 fractions of radiotherapy are given.
Study: NCT01834469
Drug: iv injection of ICG
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: An iv injection will be performed for the ovarian cancer patient before the operation.
Study: NCT02056665
Drug: MINOCYCLINE
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pill Minocycline 50 mg capsule
Study: NCT02056665
Drug: PLACEBO (for Minocycline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill manufactured to mimic Minocycline 50 mg capsule
Study: NCT03700294
Drug: ADCT-601
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV)
Study: NCT00973752
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenously during Induction, CNS, and Consolidation 2 therapy
Study: NCT00973752
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecally during Induction, CNS, and Continuation Therapy
Study: NCT00973752
Drug: 6 Mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally during CNS, Consolidation 2 and Continuation Therapy
Study: NCT02365272
Drug: Amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin administered in a single dose for critical care patients
Study: NCT00703781
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile ophthalmic solution
Study: NCT04322266
Drug: HCP1701
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe / Rosuvastatin / Amlodipine / Losartan potassium